Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic valve

Valvular Aortic valve

View Category

Structural heart disease

EuroPCR 2018 | NOTION: Good TAVR Durability Compared with Surgically-Implanted Valve in Low-Risk Patients

Several studies are defining the role of transcatheter aortic valve replacement (TAVR) in patients with low surgical...
solaci -
Learn More
Structural heart disease

Is TAVR Durable Beyond 5 Years?

Courtesy of Dr. Carlos Fava. The benefits derived from transcatheter aortic valve replacement (TAVR) are clear and self-evident, and...
solaci -
Learn More
Structural heart disease

Baseline Pulmonary Hypertension Should Not Preclude TAVR

Pulmonary hypertension (PH) in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) should not...
solaci -
Learn More
Structural heart disease

Liver Failure as a Challenge for TAVR

Although surgical risk scores do not include liver failure (LF), patients who suffer from it and undergo...
solaci -
Learn More
Structural heart disease

TAVR with Prior MRS: A New Challenge

The benefits of transcatheter aortic valve replacement (TAVR) for high-risk, prohibitive-risk (class I) or intermediate-risk (class IIa) patients have...
solaci -
Learn More
Structural heart disease

Bicuspid Valves Do Not Increase Mortality in TAVR

The frequency of bicuspid aortic valves (BcAV) are around 1%, but in 60+ patients it is associated...
solaci -
Learn More
Mitral valve

We Should Consider Mitral Stenosis Before TAVR

The association between aortic stenosis and some degree of mitral stenosis (MS) is around 10% (depending on...
solaci -
Learn More
Structural heart disease

Morbidity and Mortality During Authorization Wait-Times for TAVR

For this Canada-based study, the increased number of patients who required a transcatheter aortic valve replacement (TAVR)...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Dr. Juan Manuel Pérez - 0
Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Dr. Juan Manuel Pérez - 0
Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become...

Is it safe to use negative chronotropic drugs early after TAVI?

Dr. Juan Manuel Pérez - 0
TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy